In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on AN2 Therapeutics, Inc. (ANTX – Research Report). The company’s shares opened today at $2.34.
According to TipRanks, Baral is a 4-star analyst with an average return of 6.5% and a 43.18% success rate. Baral covers the Healthcare sector, focusing on stocks such as Neurogene, Milestone Pharmaceuticals, and COMPASS Pathways.
Currently, the analyst consensus on AN2 Therapeutics, Inc. is a Moderate Buy with an average price target of $5.50.
The company has a one-year high of $22.22 and a one-year low of $2.20. Currently, AN2 Therapeutics, Inc. has an average volume of 342.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AN2 Therapeutics, Inc. (ANTX) Company Description:
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Read More on ANTX:
